Key facts
- Tyligand Bioscience’s last known valuation is $222.2M (Jan 2026).
- It has raised $110.6M; the latest was IPO in Jan 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, K2VC, Tailong VC, Suzhou Yuanfeng Capital Management, VI Ventures — 14 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Tyligand Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Tyligand Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tyligand Bioscience
Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. The company provides clinical-stage drug candidates and a differentiated therapeutic pipeline, enabling cancer patients and healthcare providers with novel treatment mechanisms, improved survival outcomes, and solutions for unmet clinical needs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 64
- Website
- tyligand.com.cn/
- Ownership
- In IPO Registration
Tyligand Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tyligand Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tyligand Bioscience in its N-PORT filings yet. We sweep new filings monthly.